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Abstract: 3,5-Disubstituted 4-fluoroisoxazole, 4,4,5-trifluoroisoxazoline and 4,4-difluoro-5-
hydroxyisoxazoline products were obtained from reaction of the corresponding isoxazoles with 
SelectfluorTM depending upon the reaction conditions.  Although the fluorinations proceeded using 
conventional heating, microwave (µW) irradiation considerably shortened reaction times and 
enabled a high yielding one-pot cascade fluorination-cyclization from simple diketone substrates. In 
addition, a related 4-fluoroisoxazole-3-carboxyamide derivative was synthesized. 
 
Keywords: fluoroheteroaromatic; selective fluorination; 4-fluoroisoxazole; 4,4,5-
trifluoroisoxazoline TRPV1 antagonist. 
 
1. Introduction 
There is a continuing requirement for the development of efficient and environmentally benign 
routes for the synthesis of novel fluorinated aromatic and heterocyclic systems for incorporation 
into life science discovery programs, because many fluorinated pharmaceutical and agrochemical 
substances contain such structural units.1  For the purpose of synthesizing fluorinated compounds, 
electrophilic fluorinating agents of the N-F class such as N-fluoropyridinium salts (F-Py-X), 
                                                          
∗ Corresponding author. Tel.: +81-72-866-3142; fax: +81-72-866-3142; e-mail: sato@pharm.setsunan.ac.jp 
∗ Corresponding author. Tel.: +44-0191-334-2039; fax: +44-0191-384-4737; e-mail: graham.sandford@durham.ac.uk 
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SelectfluorTM and NFSI are commonly used by medicinal chemists due to the relative ease of 
handling these shelf-stable, solid reagents and wide commercial availability.  Many fluorinated 6-
membered heteroaromatic derivatives find applications in a wide variety of drugs and plant 
protection systems and, consequently, there are many examples of the synthesis of fluorinated 6-
membered heteroaromatic rings by selective fluorination strategies in the literature as typified by 
the preparation of a range of fluoro-pyridine and -pyrimidine systems.2,3  On the other hand, 
selective fluorination of 5-membered heteroaromatic systems is rare and, in particular, there are 
only very few reports concerning the synthesis of fluorinated 5-membered heteroaromatic systems 
that have two ring heteroatoms, such as fluoro-pyrazoles, isoxazoles and thiazole derivatives.4–6 
We recently reported selective fluorination of pyrazoles using fluorine gas or SelectfluorTM to 
give 4-fluoropyrazole or 4,4-difluoro-1H-pyrazole derivatives depending on the reaction conditions 
in moderate to good yields (Scheme 1).7 As part of a wider research programme aimed at 
synthesizing fluorinated 5-membered heteroaromatic systems, in this paper, we report our studies 
concerning the fluorination of isoxazoles using SelectfluorTM. 
 
 
Scheme 1. Selective fluorination of pyrazoles. 
 
Studies concerning the synthesis of fluoroisoxazole derivatives are very rare, despite the potential 
utility of these systems in the life science industries. Reactions of fluorinated building blocks 
provide two methods for the synthesis of fluoroisoxazoles: condensation of 2-fluoro-1,3-dicarbonyl 
derivatives with hydroxylamine was reported by Bumgardner5a and, more recently, gold catalyzed 
fluorocyclization of 2-alkyne O-methyloximes gave rise to 4-fluoroisoxazole products5b. Only a 
very few examples of the most direct method for synthesizing fluoro-isoxazoles by electrophilic 
fluorination have been reported by Stephens.5c Low yields of fluoroisoxazoles were prepared using 
SelectfluorTM and a trifluorinated system was obtained as a minor by-product in one of their 
syntheses. In contrast, it was reported5b that attempted gold catalyzed electrophilic fluorination of 
3,5-diphenylisoxazole gave no fluorinated product upon reaction with SelectfluorTM and reaction of 
related phenylisoxazoles with SelectfluorTM in acetonitrile were not successful, demonstrating the 
difficulty of carrying out such potentially simple transformations. Therefore, given conflicting 
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literature reports, we aimed to develop general, robust and accessible procedures for the synthesis of 
fluoro-isoxazoles by electrophilic fluorination reactions. 
 
2. Results and Discussion 
Following our results concerning the fluorination of pyrazoles7, the corresponding 3,5-
diphenylisoxazole (1a) was fluorinated in a similar manner by using SelectfluorTM assisted by 
microwave (µW) irradiation to give 3,5-diphenyl-4-fluoroisoxazole (2a) in moderate yield.  
Reaction conditions were optimized with respect to reaction time, solvent and reaction temperature 
as shown in Table 1. 
 
Table 1.  Fluorination of 3,5-diphenyl-4-fluoroisoxazole and reaction optimization. 
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Some N-fluoropyridinium salts (F-Py-X) and NFSI fluorinating agents were ineffective in 
bringing about fluorination, but the desired product (2a) was obtained in moderate yield by using 
SelectfluorTM (entries 1–9).  Sulfolane was found to be the most effective solvent for this reaction 
(entries 10–14). In attempts to improve the yield various salts such as NaOTf, AgOTf, Sc(OTf)3 and 
NaOEt were added to the reaction mixture, but these additives did not improve the yield of 
fluoroisoxazole product.  Simple heating by conventional oil bath also gave the desired 
fluoroisoxazole product in similar yield as shown in entries 15–18. These results contrast with 
earlier reports5b regarding the fluorination of reaction of (1a) with SelectfluorTM. 
Using the optimized conditions (Table 1, entry 17 : sulfolane, 120 °C, 1 h), fluorination of several 
related isoxazoles were investigated and the results are summarized in Table 2. 
 
Table 2.  Selective fluorination of isoxazoles. 
 
 
3,5-Diarylisoxazoles that have electron donating group substituents gave the desired products in 
slightly higher yields in comparison to substrates bearing electron withdrawing groups, as would be 
expected for an electrophilic substitution process.  A stronger donating group such as -OMe gave 
significant quantities of tar that decreased the yield of (2b), but milder reaction conditions (90 °C, 2 
h) improved the yield.   
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Figure 1.  Molecular structure of 4-fluoro-3,5-di-(p-chlorphenyl)isoxazole (2d) and different 
packing motifs in crystal structures of (2a), (2c) and (2d). 
 
For isoxazole substrates bearing other alkyl substituents, fluorination reactions gave the desired 
fluoroisoxazoles (2c–f) in moderate yields. All monofluorinated isoxazole products were isolated by 
column chromatography and characterized by NMR and mass spectrometry.  In addition, the 
molecular structures of compounds (2a), (2c) and (2d) were confirmed by X-ray crystallography 
(Fig. 1). All these molecules are essentially planar, show similar N/O disorder in the heterocycle 
and π…π aromatic stacking interactions occur in the crystal. Nevertheless, the crystal packing in 
each system is quite different: molecules (2a) form layers of herring-bone packed molecules, in (2c) 
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disordered molecules are linked into aromatic stacks, while the layers in structure (2d) are 
constructed from herring-bone packed antiparallel dimers. 
In attempts to increase the yield of the monofluorinated systems, we found that using an excess 
amount of SelectfluorTM gave another type of fluorinated system, 4,4,5-trifluoroisoxazolines (3), 
rather than increased amounts of 4-fluoroisoxazole products.  Generation of a single 4,4,5-
trifluoroisoxazoline derivative (3) was reported as a side product in a previous paper by Stephens 
and coworkers.5c  In our case, products (3) were obtained in moderate to good yields using an 
excess amount of SelectfluorTM and the results are summarized in Table 3. 3,5-Di-p-
methoxyphenylisoxazole and 3-methyl-5-phenylisoxazole (1b and 1f) gave a complex mixture of 
products and, (3b) and (3f) were obtained in low yield, respectively. The use of milder conditions in 
acetonitrile (reflux, 90 °C) improved the yield of the trifluorinated systems considerably. However, 
p-trifluoromethyl substituents seriously decreased the reactivity of the isoxazole substrate and, 
consequently, the 4-fluoroisoxazole (2e) was isolated in low yield rather than the 
trifluoroisoxazoline (3e). 
 
Table 3.  Selective fluorination of various isoxazoles using excess amount of SelectfluorTM. 
 
 
It was important to very rigorously dry the sulfolane solvent by vacuum distillation over sodium 
wire before attempting this trifluorination process because, when moist sulfolane was used (dry 
sulfolane from chemical suppliers used as received), a hydroxylated derivative was obtained after 
purification by column chromatography (Scheme 2). 
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Scheme 2. Synthesis of 4,4-difluoro-3,5-bis(phenyl)-isoxazol-5-ol derivatives (4). 
 
 
The structures of 4a and 4c were confirmed by X-ray crystallography (Fig. 2). Both molecules 
adopt almost identical conformations in their crystals and are linked by O-H…N hydrogen bonds 
into infinitive chains. 
 
 
 
Figure 2.  Molecular structure of 4,4-difluoro-3,5-diphenyl-isoxazol-5-ol (4a) and packing of the 
molecules in the crystal (hydrogen bonds are shown in dotted lines). 
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A mechanism for the formation of the monofluoro-, trifluoro and difluoro-hydroxyl systems is 
given in Scheme 2. Initial fluorination of the isoxazoles (1) gives the monofluorinated product (2) 
by a typical electrophilic aromatic substitution process.  Since 4-fluoroisoxazoles are still 
significantly reactive towards electrophiles, reaction with a second equivalent of electrophilic 
fluorinating reagent SelectfluorTM gives difluorinated intermediates which are immediately trapped 
by fluoride ion to give 4,4,5-trifluoroisoxazolines (3) (Scheme 3). The source of fluoride ion in 
these reactions is most probably derived from the BF4- counterion of SelectfluorTM.  The presence of 
any water in the sulfolane reaction medium gives rise to the hydroxyl group in (4). 
 
 
Scheme 3. Proposed mechanism for selective fluorination of isoxazoles. 
 
To provide a more consistent and readily operated synthesis of 4-fluoroisoxazole derivatives, we 
assessed a one-pot synthesis of 4-fluoroisoxazole 2 from the corresponding diketone 5 which in 
case of (5c), R=R’=p-Tol exists in the disordered enol form in the crystal (Fig. 3). 
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Figure 3. Molecular structure of diketone 5c (R=R’=p-Tol, both components of disordered 
hydrogen atoms are shown). 
 
Fortunately, reaction of diketone (5), hydroxylamine and SelectfluorTM in a single-pot, µW 
assisted process provided a great improvement in the yield of fluoroisoxazole as shown in Table 4. 
By this one-pot process, 4-fluorinated isoxazoles were obtained together with a small amount of 
monofluorodiketone derivative in most cases but, even when 3 equivs. of SelectfluorTM was used, 
the corresponding 4,4,5-trifluoroisoxazolines (3) were not obtained. The presence of 
monofluorinated diketones in the reaction mixtures, as observed by 19F NMR spectroscopy, 
indicates that fluorination of the diketone substrates occurs before cyclisation leading to higher 
yields of the desired fluoroisoxazole products. 
 
Table 4.  One-pot synthesis of 4-fluoroisoxazole derivatives (2). 
 
 
Based on the successful fluorination of isoxazoles, we used our methodology for the synthesis of 
a biologically active fluoroisoxazole system.  Transient receptor potential vanilloid 1 (TRPV1) is a 
Ca2+ permeant non-selective cation channel expressed in a subpopulation of primary afferent 
neurons and led to the cloning of the first vanilloid (capsaicin) receptor by Julius and colleagues in 
1997.8  Recently a new series of TRPV1 antagonists that are expected to aid in management of 
acute and chronic pain was reported and, 4-fluoroisoxazole-3-carboxyamides showed moderate 
potency in a TRPV1 assay.9  Using the synthetic methodology described above, we targeted the 
synthesis of 4-fluoroisoxazole-3-carboxyamide (2j) following the strategy shown in Scheme 4 
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because this system has been reported to be a potent TRPV1 antagonist.9b  Reaction of diethyl 
oxalate and p-trifluoromethylacetophenone to form the corresponding diketoester (8) was followed 
by condensation with hydroxylamine hydrochloride to give the isoxazole (1j).  Hydrolysis and 
amidation of 1j gave the corresponding isoxazole-3-carboxyamide (1k).  The fluorination of 1k as 
the final stage gave a desired TRPV1 antagonist (2k), although its yield was very low.  To improve 
the yield, 1j or related 3-hydroxymethyl-isoxazole (1l), were used as the substrates but no 
fluoroisoxazole products were obtained. Unfortunately, our one-pot strategy also failed to give 
higher yields of (2k) from (8) despite many attempts using a range of reaction conditions. 
 
Scheme 4. Synthesis of 4-fluoroisoxazole-3-carboxyamide as a TRPV1 antagonist. 
 
 
3. Conclusions 
In conclusion, we demonstrated that the C-4 fluorination of 3,5-disubstituted isoxazoles is 
possible when SelectfluorTM is used as the fluorinating agent using both conventional oil bath 
heating and µW irradiation.  We also showed that using an excess amount of SelectfluorTM gave the 
corresponding 4,4,5-trifluoroisoxazolines in moderate to good yields if thoroughly dry sulfolane is 
used as the reaction medium.  The synthesis of 4-fluoroisoxazole derivatives can best be achieved in 
high yields by a one-pot process involving heating the 1,3-diketone substrate, SelectfluorTM and 
hydroxylamine in sulfolane using microwave heating. 
 
4. Experimental 
4.1 General Information 
1H NMR and 13C NMR spectra were recorded on JNM-GX400 spectrometers.  19F NMR spectra 
were recorded on Hitachi FT-NMR R-90H and Bruker 400 Ultrashield spectrometers.  Chemical 
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shifts of 1H NMR and 13C NMR are reported in ppm from tetramethylsilane (TMS: 0 ppm) as an 
internal standard.  Chemical shifts of 19F NMR are reported in ppm from benzotrifluoride (BTF: 0 
ppm) as an internal standard unless otherwise noted.  All data are reported as follows: chemical 
shifts, relative integration value, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, br = 
broad, m = multiplet), coupling constants (Hz).  Mass spectra were obtained on JEOL JMS-700T 
spectrometers and a Trace GC-MS device (Thermo-Finnigan Corporation) operating in electron 
impact ionization (EI) mode. Accurate mass analysis was performed on a Xevo QtoF mass 
spectrometer (Waters Ltd, UK) with an accurate solids analysis probe (ASAP). Melting points were 
measured on Yanagimoto micro melting point apparatus MP-S3.  IR spectra were recorded on 
JASCO FT/IR-410 spectrophotometer.  Analytical gas-liquid chromatography (GLC) was carried 
out on Hitachi G-3500 gas chromatograph (column; TO-5 0.25 mm x 15 m, carrier; He at 2.2 
ml/min).  Peak areas were calculated on Hitachi D-2500 Chromato-integrator.  Microwave reactions 
were performed in microwave tubes with clip lids using Biotage Initiator microwave reactor.  All 
commercially available reagents were used without further purification.  All experiments were 
carried out under argon atmosphere unless otherwise noted. 
 
4.2 General procedure for selective fluorination of isoxazoles to synthesise 2 assisted by µW 
irradiation. 
Isoxazole (1; 1 mmol) and SelectfluorTM (1 mmol) were added to a microwave vial and 
suspended in sulfolane (4 mL).  The vial was sealed and heated by microwave irradiation for 15 
minutes at 150 °C.  The resulting mixture was quenched with NaHCO3 and, extracted with AcOEt.  
The AcOEt layer was washed with brine and dried over MgSO4.  The solvent was removed in vacuo 
and the residue was purified by column chromatography to give 4-fluoroisoxazole (2). 
 
4.3 General procedure for selective fluorination of isoxazoles to synthesise 2 heated by oil bath. 
Under an Ar atomosphere, isoxazole (1; 1 mmol) and SelectfluorTM (1 mmol) were suspended in 
sulfolane (4 mL) and stirred for 1 h at 120 °C.  The resulting mixture was quenched with NaHCO3 
and, extracted with AcOEt.  The AcOEt layer was washed with brine and dried over MgSO4.  The 
solvent was removed in vacuo and the residue was purified by column chromatography to give 4-
fluoroisoxazole (2). 
 
4.4 General procedure for the synthesis of 4,4,5-trifluoroisoxazolines 3. 
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Under an Ar atomosphere, isoxazole (1; 1 mmol) and SelectfluorTM (3 mmol) were suspended in 
sulfolane (4 mL) and stirred for 1 h at 120 °C.  The resulting mixture was quenched with NaHCO3 
and, extracted with AcOEt.  The AcOEt layer was washed with brine and dried over MgSO4.  The 
solvent was removed in vacuo and the residue was purified by column chromatography to give 4-
fluoroisoxazole (3). 
 
4.5 General procedure for the synthesis of 4,4-difluoroisoxazol-5-ols 4. 
A mixture comprising of isoxazole (1, 1 mmol) and SelectfluorTM (3 mmol) in moist sulfolane (4 
mL) was irradiated by microwave heating at 150 °C for 1 h. The product was extracted into 
chloroform, washed sequentially with sat. NaHCO3 and brine, then dried (MgSO4) and the solvent 
was removed in vacuo. Column chromatography on silica gel using hexane:ether:triethylamine 
(70:10:1) as eluent gave the 5-hydroxyl product (4). 
 
4.6 General procedure for the one-pot synthesis of 4-fluorinated isoxazoles 2 assisted by µW 
irradiation. 
Diketone (5; 1 mmol), hydroxylamine hydrochloride (3 mmol) and SelectfluorTM (1 mmol) were 
added to a microwave vial and suspended in sulfolane (4 mL).  The vial was sealed and heated by 
microwave irradiation for 15 minutes at 150 °C.  The resulting mixture was quenched with 
NaHCO3 and, extracted with AcOEt.  The AcOEt layer was washed with brine and dried over 
MgSO4.  The solvent was removed in vacuo and the residue was purified by column 
chromatography to give 4-fluoroisoxazole (2). 
 
4.7 Synthesis of ethyl 5-(4-(trifluoromethyl)phenyl)isoxazole-3-carboxylate (1j). 
Under an Ar atomosphere, to a solution of p-trifluoromethylacetophenone (6; 2 mmol) and 
diethyl oxalate (7; 4 mmol) in THF (10 mL) was added 1.3 M of LiHMDS in THF (1.69 mL, 2.2 
mmol) at -78 °C.  The resulting mixture was gradually warmed to rt and stirred for 16 h.  The 
mixture was quenched with 10% HCl and, extracted with AcOEt.  The AcOEt layer was washed 
with brine and dried over MgSO4.  The solvent was removed in vacuo and, then the reaction residue 
was dissolved in EtOH (2 mL) and H2O (3 mL).  NH2OH·HCl (278 mg, 4 mmol) was added and the 
resulting solution was heated at reflux for 16 h.  The resulting mixture was quenched with brine and 
extracted with AcOEt, then dried over MgSO4.  The solvent was removed in vacuo and the residue 
was purified by column chromatography (SiO2) to give the product (1j) (190 mg, 33 %). 
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4.8 Synthesis of N-cyclopentyl-5-(4-(trifluoromethyl)phenyl)isoxazole-3-carboxamide (1k). 
To a solution of 1j (285 mg, 1 mmol) in THF (5 mL) was added a solution of LiOH (71 mg, 1.7 
mmol) in H2O (5 mL) at rt and, the mixture was stirred for 1 h.  The resulting mixture was 
quenched with 10% HCl, and extracted with AcOEt.  The AcOEt layer was washed with brine and 
dried over MgSO4.  The solvent was removed in vacuo and, then the reaction residue was dissolved 
in CH2Cl2 (8 mL).  A solution of oxalyl chloride (0.25 mL, 3 mmol) in CH2Cl2 (1.5 mL) was added 
to the residue solution and stirred for 20 min.  A few drops of DMF were added and the mixture 
was stirred for 2 h at rt.  The solvent was removed in vacuo and the residue was dissolved in 
CH2Cl2 (8 mL).  Et3N (0.5 mL) and cyclopentylamine (5 mL) were added and the solution was 
stirred for 16 h at rt.  The resulting mixture was quenched with 10% HCl and extracted with AcOEt, 
then dried over MgSO4.  The solvent was removed in vacuo and the residue was purified by column 
chromatography (SiO2) to give the product (1k) (300 mg, 93 %). 
 
5. Spectroscopic Data 
 
5.1 Ethyl 5-(4-(trifluoromethyl)phenyl)isoxazole-3-carboxylate (1j). (0.09 g, 33%); colorless 
solid; M.p. 133.0–134.0 °C (recrystallized from EtOH); 1H NMR (CDCl3) δ: 1.46 (3H, t, J = 7.1 
Hz), 4.50 (2H, q, J = 7.1 Hz), 7.04 (1H, s), 7.76–7.78 (2H, m), 7.93–7.96 (2H, m); 13C NMR (100 
MHz, CDCl3) δ: 14.46, 62.67, 101.6, 123.7 (q, J = 271.7 Hz), 126.4 (q, J = 3.8 Hz), 126.4, 129.8 (q, 
J = 1.3 Hz), 132.6 (q, J = 32.9 Hz), 157.3, 159.8, 170.1; 19F NMR (90 MHz, CDCl3) δ: -0.31 (3F, 
s); MS m/z: 285 (M+); HRMS Calcd for C13H10F3NO3: 285.0613 (M+), Found: 285.0613; IR (KBr) 
cm-1: 3134, 2990, 1725. 
 
5,2 N-Cyclopentyl-5-(4-(trifluoromethyl)phenyl)isoxazole-3-carboxamide (1k). (0.30 g, 93%); 
colorless solid; M.p. 204.5–205.5 °C (recrystallized from EtOH); 1H NMR (CDCl3) δ: 1.51–1.81 
(6H, m), 2.04–2.15 (2H, m), 4.41 (1H, m), 6.78 (1H, br d, J = 6.7 Hz), 7.07 (1H, s), 7.75–7.77 (2H, 
m), 7.91–7.93 (2H, m); 13C NMR (100 MHz, CDCl3) δ: 23.74, 33.01, 51.33, 100.5, 123.5 (q, J = 
271.7 Hz), 126.0 (q, J = 3.8 Hz), 126.1, 129.7 (q, J = 1.3 Hz), 132.2 (q, J = 32.9 Hz), 157.8, 159.3, 
169.6; 19F NMR (90 MHz, CDCl3) δ: -0.30 (3F, s); MS m/z: 324 (M+); HRMS Calcd for 
C16H15F3N2O2: 324.1086 (M+), Found: 324.1084. 
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5.3 4-Fluoro-3,5-diphenylisoxazole (2a). (0.10 g, 44%); colorless solid; M.p. 102.0–103.0 °C 
(recrystallized from EtOH); 1H NMR (CDCl3) δ: 7.45–7.55 (6H, m), 7.88–7.90 (2H, m), 7.94–7.97 
(2H, m); 13C NMR (100 MHz, CDCl3) δ: 125.4 (d, J = 4.9 Hz), 126.1 (d, J = 5.1 Hz), 127.0 (d, J = 
3.9 Hz), 127.2 (d, J = 3.5 Hz), 129.1 129.2, 130.3 (d, J = 1.1 Hz), 130.6, 141.7 (d, J = 258.7 Hz), 
153.3 (d, J = 10.6 Hz), 153.7 (d, J = 19.3 Hz); 19F NMR (90 MHz, CDCl3) δ: -115.4 (1F, s); MS 
m/z: 239 (M+); HRMS Calcd for C15H10NOF: 239.0746 (M+), Found: 239.0755; IR (KBr) cm-1: 
3067, 1466, 1215. 
 
5.4 4-Fluoro-3,5-bis(4-methoxyphenyl)isoxazole (2b). (0.12 g, 41%); colorless solid; M.p. 
137.0–138.0 °C (recrystallized from EtOH); 1H NMR (CDCl3) δ: 3.88 (3H, s), 3.88 (3H, s), 7.02–
7.05 (4H, m), 7.80–7.90 (4H, m); 13C NMR (100 MHz, CDCl3) δ: 55.6, 55.7, 114.6, 114.7, 119.1 
(d, J = 5.1 Hz), 119.7 (d, J = 3.9 Hz), 127.1 (d, J = 4.8 Hz), 128.7 (d, J = 3.7 Hz), 140.7 (d, J = 
255.4 Hz), 152.9 (d, J = 10.5 Hz), 153.5 (d, J = 19.7 Hz), 161.0 (d, J = 1.5 Hz), 161.4; 19F NMR (90 
MHz, CDCl3) δ: -117.5 (1F, s); MS m/z: 299 (M+); HRMS Calcd for C17H14NO3F: 299.0958 (M+), 
Found: 299.0959; IR (KBr) cm-1: 2973, 2944, 1648, 1609, 1516, 1467, 1252. 
 
5.5 4-Fluoro-3,5-di-p-tolylisoxazole (2c). (0.11 g, 44%); colorless solid; M.p. 152.5–153.0 °C 
(recrystallized from EtOH); 1H NMR (CDCl3) δ: 2.43 (6H, s), 7.31–7.34 (4H, m), 7.76–7.84 (4H, 
m); 13C NMR (100 MHz, CDCl3) δ: 21.50, 21.54, 123.1 (d, J = 5.0 Hz), 123.9 (d, J = 3.9 Hz), 125.0 
(d, J = 4.9 Hz), 126.7 126.8, 129.5 (d, J = 5.3 Hz), 140.2 (d, J = 1.3 Hz), 140.5, 141.0 (d, J = 256.8 
Hz), 152.9 (d, J = 10.5 Hz), 153.4 (d, J = 19.4 Hz); 19F NMR (90 MHz, CDCl3) δ: -116.1 (1F, s); 
MS m/z: 267 (M+); HRMS Calcd for C17H14NOF: 267.1059 (M+), Found: 267.1068; IR (KBr) cm-1: 
1647, 1614, 1514, 1470. 
 
5.6 3,5-Bis(4-chlorophenyl)-4-fluoroisoxazole (2d). (0.11 g, 35%); colorless solid; M.p. 170.0–
172.0 °C (recrystallized from EtOH); 1H NMR (CDCl3) δ: 7.48–7.53 (4H, m), 7.80–7.83 (2H, m), 
7.87–7.89 (2H, m); 13C NMR (100 MHz, CDCl3) δ: 124.3 (d, J = 5.1 Hz), 125.2 (d, J = 4.0 Hz), 
126.7 (d, J = 5.0 Hz), 128.5 (d, J = 3.7 Hz), 129.6, 129.7, 136.6 (d, J = 1.9 Hz), 137.0 (d, J = 0.7 
Hz), 141.6 (d, J = 258.7 Hz), 152.5 (d, J = 10.5 Hz), 153.0 (d, J = 19.4 Hz); 19F NMR (90 MHz, 
CDCl3) δ: -114.6 (1F, s); MS m/z: 307 (M+); HRMS Calcd for C15H8NOCl2F: 306.9967 (M+), 
Found: 306.9969; IR (KBr) cm-1: 1651, 1599, 1496, 1457, 1092. 
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5.7 4-Fluoro-3,5-bis(4-(trifluoromethyl)phenyl)isoxazole (2e). (0.06 g, 16%); colorless solid; 
M.p. 156.0–157.0 °C (recrystallized from EtOH); 1H NMR (CDCl3) δ: 7.79–7.82 (4H, m), 8.00–
8.09 (4H, m); 13C NMR (100 MHz, CDCl3) δ: 123.5 (q, J = 271.7 Hz), 123.5 (q, J = 271.6 Hz), 
125.4 (d, J = 5.2 Hz), 125.9 (q, J = 3.8 Hz), 126.1 (q, J = 3.8 Hz), 127.3 (d, J = 3.7 Hz), 128.5 (m), 
129.6 (m), 131.9 (qd, J = 32.8, 1.5 Hz), 132.4 (q, J = 32.8 Hz), 142.1 (d, J = 261.1 Hz), 152.1 (d, J 
= 10.4 Hz), 152.5 (d, J = 19.5 Hz); 19F NMR (90 MHz, CDCl3) δ: -0.29 (6F, s), -113.1 (1F, s); MS 
m/z: 375 (M+); HRMS Calcd for C17H8NOF7: 375.0494 (M+), Found: 375.0498; IR (KBr) cm-1: 
1650, 1619, 1538, 1321, 1175, 1136. 
 
5.8 4-Fluoro-3-methyl-5-phenylisoxazole (2f). (0.07 g, 71%); colorless oil; 1H NMR (CDCl3) δ: 
2.37 (3H, d, J = 0.5 Hz), 7.40–7.51 (3H, m), 7.79–7.82 (2H, m); 13C NMR (100 MHz, CDCl3) δ: 
8.70 (d, J = 5.8 Hz), 125.0 (d, J = 4.8 Hz), 125.8 (d, J = 5.0 Hz), 128.8, 129.7 (d, J = 1.3 Hz), 142.1 
(d, J = 254.9 Hz), 151.7 (d, J = 15.9 Hz), 151.8 (d, J = 18.2 Hz); 19F NMR (90 MHz, CDCl3) δ: -
118.3 (1F, s); MS m/z: 177 (M+); HRMS Calcd for C10H8FNO: 177.0590 (M+), Found: 177.0586. 
 
5.9 N-Cyclopentyl-4-fluoro-5-(4-(trifluoromethyl)phenyl)isoxazole-3-carboxamide (2k). (0.01 g, 
4%); colorless solid; M.p. 188.5–189.0 °C (recrystallized from MeOH); 1H NMR (CDCl3) δ: 1.52–
1.78 (6H, m), 2.07–2.15 (2H, m), 4.42 (1H, m), 6.62 (1H, br d, J = 6.1 Hz), 7.78–7.80 (2H, m), 
7.96–7.98 (2H, m); 13C NMR (100 MHz, CDCl3) δ: 23.7, 33.0, 51.3, 123.4 (q, J = 271.8 Hz), 125.4 
(d, J = 4.8 Hz), 126.1 (q, J = 3.8 Hz), 128.1 (m), 132.1 (m), 142.1 (d, J = 266.6 Hz), 148.7 (d, J = 
8.5 Hz), 153.5 (d, J = 17.9 Hz), 156.2 (d, J = 3.7 Hz); 19F NMR (90 MHz, CDCl3) δ: -0.37 (3F, s), -
111.0 (1F, s); MS m/z: 342 (M+); HRMS Calcd for C16H14F4N2O2: 342.0991 (M+), Found: 
342.0995. 
 
5.10 4,4,5-Trifluoro-3,5-diphenyl-4,5-dihydroisoxazole (3a). (0.22 g, 78%); colorless oil; 1H 
NMR (CDCl3) δ: 7.48–7.58 (6H, m), 7.66–7.68 (2H, m), 7.88–7.90 (2H, m); 13C NMR (100 MHz, 
CDCl3) δ: 111.3 (ddd, J = 241.5, 36.5, 21.1 Hz), 124.1 (m), 124.8 (ddd, J = 290.5, 256.1, 34.4 Hz), 
127.3 (m), 127.4 (d, J = 1.7 Hz), 128.3 (m), 128.9, 129.5, 131.4 (d, J = 1.7 Hz), 132.5, 154.8 (dd, J 
= 25.6, 23.7 Hz); 19F NMR (90 MHz, CDCl3) δ: -38.4 (1F, dd, J = 273, 8 Hz), -52.9 (1F, dd, J = 8, 
3 Hz), -61.0 (1F, dd, J = 273, 3 Hz); MS m/z: 277 (M+); HRMS Calcd for C15H10NOF3: 277.0714 
(M+), Found: 277.0716; IR (neat) cm-1: 3067, 1140, 1057, 1039. 
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5.11 4,4,5-Trifluoro-3,5-bis(4-methoxyphenyl)-4,5-dihydroisoxazole (3b). (0.20 g, 59%); 
colorless solid; M.p. 59.5–61.5 °C (recrystallized from hexane); 1H NMR (CDCl3) δ: 3.86 (s, 3H), 
3.87 (s, 3H), 6.99–7.02 (4H, m), 7.56–7.59 (2H, m), 7.82–7.84 (2H, m); 13C NMR (100 MHz, 
CDCl3) δ: 55.31, 55.39, 111.0 (ddd, J = 239.7, 36.1, 21.2 Hz), 113.9, 114.6, 116.1 (dd, J = 3.0, 1.4 
Hz), 119.9 (dd, J = 27.9, 0.9 Hz), 124.4 (ddd, J = 271.9, 254.6, 35.4 Hz), 128.4 (dd, J = 5.2, 1.4 
Hz), 128.7 (d, J = 1.9 Hz), 154.0 (dd, J = 25.3, 23.7 Hz), 161.5 (d, J = 1.8 Hz), 162.5; 19F NMR (90 
MHz, CDCl3) δ: -38.3 (1F, dd, J = 273, 8 Hz), -51.6 (1F, dd, J = 8, 4 Hz), -61.0 (1F, dd, J = 273, 4 
Hz); MS m/z: 337 (M+); HRMS Calcd for C17H14F3NO3: 337.0926 (M+), Found: 337.0923; IR 
(KBr) cm-1: 2967, 2936, 1613, 1518, 1265. 
 
5.12 4,4,5-Trifluoro-3,5-di-p-tolyl-4,5-dihydroisoxazole (3c). (0.17 g, 56%); colorless solid; M.p. 
73.0–74.0 °C (recrystallized from MeOH); 1H NMR (CDCl3) δ: 2.42 (m, 6H), 7.29–7.31 (4H, m), 
7.53–7.55 (2H, m), 7.76–7.78 (2H, m); 13C NMR (100 MHz, CDCl3) δ: 21.39, 21.65, 110.6 (ddd, J 
= 240.2, 36.2, 21.1 Hz), 120.9 (m), 124.5 (ddd, J = 272.1, 255.0, 34.7 Hz), 125.0 (m), 126.8 (m), 
126.9 (d, J = 1.8 Hz), 129.1, 129.8, 141.2 (d, J = 1.8 Hz), 142.7, 154.4 (dd, J = 25.5, 23.6 Hz); 19F 
NMR (90 MHz, CDCl3) δ: -38.4 (1F, dd, J = 273, 8 Hz), -52.4 (1F, dd, J = 8, 4 Hz), -61.1 (1F, dd, J 
= 273, 4 Hz); MS m/z: 305 (M+); HRMS Calcd for C17H14F3NO: 305.1027 (M+), Found: 305.1035; 
IR (KBr) cm-1: 2969, 1136, 1042. 
 
5.13 3,5-Bis(4-chlorophenyl)-4,4,5-trifluoro-4,5-dihydroisoxazole (3d). (0.23 g, 66%); colorless 
solid; M.p. 111.0–111.5 °C (recrystallized from hexane); 1H NMR (CDCl3) δ: 7.48–7.51 (4H, m), 
7.57–7.59 (2H, m), 7.80–7.82 (2H, m); 13C NMR (100 MHz, CDCl3) δ: 110.6 (ddd, J = 241.9, 36.2, 
21.2 Hz), 121.9 (m), 124.2 (ddd, J = 272.6, 255.6, 34.1 Hz), 126.2 (m), 128.2 (d, J = 1.8 Hz), 128.3 
(m), 128.9, 129.6, 137.6 (d, J = 2.2 Hz), 138.7, 153.7 (dd, J = 25.6, 23.8 Hz); 19F NMR (90 MHz, 
CDCl3) δ: -38.5 (1F, dd, J = 274, 8 Hz), -53.0 (1F, dd, J = 8, 4 Hz), -60.9 (1F, dd, J = 274, 4 Hz); 
MS m/z: 345 (M+); HRMS Calcd for C15H8Cl2F3NO: 344.9935 (M+), Found: 344.9928; IR (KBr) 
cm-1: 3097, 1094, 1046. 
 
5.14 4,4,5-Trifluoro-3-methyl-5-phenyl-4,5-dihydroisoxazole (3f). (0.14 g, 67%); colorless oil; 1H 
NMR (CDCl3) δ: 2.23 (3H, d, J = 2.3 Hz), 7.45–7.55 (3H, m), 7.58–7.60 (2H, m); 13C NMR (100 
MHz, CDCl3) δ: 8.59 (m), 109.9 (ddd, J = 239.4, 36.3, 20.4 Hz), 123.9 (ddd, J = 270.2, 254.1, 34.6 
Hz), 126.8 (dd, J = 5.2, 1.6 Hz), 128.1 (dd, J = 27.0, 1.1 Hz), 128.4, 130.9 (d, J = 1.9 Hz) 154.4 (dd, 
J = 28.5, 24.6 Hz); 19F NMR (90 MHz, CDCl3) δ: -43.9 (1F, m), -53.8 (1F, m), -66.3 (1F, m); MS 
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m/z: 215 (M+); HRMS Calcd for C10H8F3NO: 215.0558 (M+), Found: 215.0559; IR (KBr) cm-1: 
3069, 1147, 1114, 1043. 
 
5.15 4,4-Difluoro-3,5-diphenyl-isoxazol-5-ol (4a). (0.08 g, 30%); orange powder; M.p. 103–106 
°C; 1H NMR (CDCl3) δ: 3.73 (1H, s), 7.58–7.46 (6H, m), 7.71–7.67 (2H, m), 7.89 (2H, d, J = 7.2 
Hz); 13C NMR (100 MHz, CDCl3) δ: 126.83 (d, J = 1.4 Hz), 127.04 (d, J = 1.5 Hz), 128.59, 129.08, 
130.36, 131.60; 19F (376 MHz, internal standard: CFCl3 as 0 ppm, CDCl3) δ: -100.39 (d, J = 266.3 
Hz), -120.09 (d, J = 266.3 Hz); HRMS Calcd for C15H12F2NO: 276.0841 ([MH]+), Found: 
276.0842; IR (neat) cm-1: 2982, 1450, 1365, 1242, 1127, 1098. 
 
5.16 4,4-Difluoro-3,5-bis(4'-methylphenyl)-isoxazol-5-ol (4c). (0.06 g, 19%); orange powder; 
M.p. 119–122 °C; 1H NMR (400 MHz, CDCl3) δ: 2.40 (3H, s), 2.41 (3H, s), 3.92 (1H, s), 7.30–7.24 
(4H, m), 7.54 (2H, d, J = 8.2 Hz), 7.75 (2H, d, J = 8.1 Hz); 13C NMR (100 MHz, CDCl3) δ: 21.33, 
21.62, 126.75 (d, J = 1.4 Hz), 126.95 (d, J = 1.3 Hz), 128.27, 129.79, 140.42, 142.10; 19F (376 
MHz, internal standard: CFCl3 as 0 ppm, CDCl3) δ: -100.26 (d, J = 265.6 Hz), -120.53 (d, J = 265.8 
Hz); HRMS Calcd for C17H16NF2O: 304.1140 ([MH]+), Found: 304.1137; IR (neat) cm-1: 1362, 
1243, 1128, 1091, 1027. 
 
6. X-Ray crystallography 
 
The single crystal X-ray diffraction data for the compound 5 have been collected on an Agilent 
XCalibur diffractometer (Saphire-3 CCD detector, graphite monochromator,) and for all other 
compounds on a Bruker D8 Venture (Photon 100 CMOS detector, IµS microsource, focusing 
mirrors) diffractometer using λMoKα radiation, λ =0.71073Å. All data were collected at the 
temperature 120.0(2)K maintained by Cryostream (Oxford Cryosystems) open-flow nitrogen 
cryostats. The structures was solved by direct method and refined by full-matrix least squares on F2 
for all data using SHELXTL10 and Olex211 software. All non-disordered non-hydrogen atoms were 
refined anisotropically, hydrogen atoms were placed in the calculated positions and refined in riding 
mode. The disordered atoms were refined with fixed SOF=0.5 in isotropic approximation. The 
structure 2c shows the whole molecule disorder and was refined isotropically with a number of 
geometry constrains. The crystallographic data and refinement paramaters are shown in Table 5, 
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crystallographic data for the structure have been deposited with the Cambridge Crystallographic 
Data Centre as supplementary publication CCDC-1440941-1440946. 
 
Table 5. Crystal data and structure refinement 
Compound 2a 2c 2d 4a 4c 5c 
Empirical formula C15H10FNO C17H14FNO C15H8Cl2FNO C15H11F2NO2 C17H15F2NO2 C17H16O2 
Formula weight 239.24 267.29 308.12 275.25 303.30 252.30 
Crystal system tetragonal triclinic monoclinic monoclinic monoclinic monoclinic 
Space group P41 P1 P21/c P21/c P21/n C2/c 
a/Å 17.2287(16) 4.9701(8) 14.3733(2) 8.37740(10) 12.7558(3) 11.2849(8) 
b/Å 17.2287(16) 6.9708(10) 7.58840(10) 18.4265(3) 8.4290(2) 11.8771(5) 
c/Å 23.098(2) 9.8488(13) 12.2635(3) 8.60770(10) 14.8259(4) 10.6797(7) 
α/° 90.00 86.142(11) 90.00 90.00 90.00 90.00 
β/° 90.00 85.356(12) 105.1303(13) 106.7387(15) 106.521(2) 114.044(8) 
γ/° 90.00 81.025(12) 90.00 90.00 90.00 90.00 
Volume/Å3 6856.0(11) 335.42(8) 1291.22(4) 1272.44(3) 1528.25(7) 1307.23(14) 
Z 24 1 4 4 4 4 
ρcalcg/cm
3 1.391 1.323 1.585 1.437 1.318 1.282 
μ/mm-1 0.099 0.092 0.507 0.115 0.103 0.083 
Reflections collected 86503 6768 27038 19475 19890 7898 
Independent refl., Rint 7647, 0.1995 1787, 0.0729 3765, 0.0481, 3387, 0.0372 3330,0.0585, 1745,0.0507, 
Data/restraints/parameters 7647/1/974 1787/3/117 3765/0/213 3387/0/185 3330/0/205 1745/1/94 
Goodness-of-fit on F2 1.013 1.415 1.051 1.008 1.033 1.025 
Final R1 [I≥2σ (I)] 0.0686 0.1247 0.0340 0.0422 0.0708 0.0603 
Final wR2 [all data] 0.1816 0.4073 0.0926 0.1136 0.2084 0.1784 
 
 
7. Acknowledgments 
 
We thank Durham University M. Chem. Undergraduate program for funding. 
 
 
8. References and notes 
 
1. (a) Fluorine-Containing Synthons; Soloshonok, V. A. Ed.; ACS Publications Division and 
Oxford University Press: Washington, D.C., 2005. (b) Uneyama, K. Organofluorine 
Chemistry; Blackwell Publishing: Oxford, 2006. (c) Bégué, J.-P., Bonnet-Delpon, D.; 
Bioorganic and Medicinal Chemistry of Fluorine; John Wiley & Sons Ltd.: New Jersey, 2008. 
(d) Fluorine in Medicinal Chemistry and Chemical Biology; Ojima, I., Ed.; Wiley-Blackwell: 
Chichester, 2009. 
2. For the synthesis of fluorinated pyridine: (a) Umemoto, T.; Tomizawa, G. J. Org. Chem. 
1989, 54, 1726–1731. (b) Stavber, S.; Zupan, M. Tetrahedron Lett. 1990, 31, 775–776. (c) 
Gakh, A. A.; Tuinman, A. A.; Adcock, J. L.; Compton, R. N. Tetrahedron Lett. 1993, 34, 
7167–7170. (d) O'Neill, P. M.; Storr, R. C.; Kevin Park, B. Tetrahedron 1998, 54, 4615–4622. 
(e) Fang, B.; Tao, H.; Kan, X.; Shang, Y. Heterocyclic Commun. 2004, 10, 305–306. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
19 
 
3. For the synthesis of fluorinated pyrimidine: (a) Robins, M. J.; Naik, S. R. J. Chem. Soc., 
Chem. Commun., 1972, 18–19. (b) Yemul, S. S.; Kagan, H. B. Tetrahedron Lett. 1980, 21, 
277–280. (c) Boudakian, M. M.; Hyde, G. A. J. Fluorine Chem. 1984, 25, 435–446. (d) Cabaj, 
J. E.; Wuts, P. G. M.; Henegar, K. E. J. Org. Chem. 1994, 59, 5090–5092. (e) Rangwala, H. 
S.; Giraldes, J. W.; Gurvich, V. J., J. Labelled Compd. Radiopharm. 2011, 54, 340–343. 
4. For the synthesis of fluorinated pyrazole: (a) Sloop, J. C.; Jackson, J. L.; Schmidt, R. D. 
Heteroat. Chem. 2009, 20, 341–345. (b) Qian, J.; Liu, Y.; Zhu, J. Jiang, B.; Xu, Z. Org. Lett. 
2011, 13, 4220–4223. 
5. For the synthesis of fluorinated isoxazole: (a) Bumgardner, C.L.; Sloop, J.C. J. Fluorine 
Chem. 1992, 56, 141-146. (b) Jeong, Y.; Kim, B.-I.; Lee, J. K.; Ryu, J.-S. J. Org. Chem. 2014, 
79, 6444–6455. (c) Stephens, C. E.; Blake, J. A. J. Fluorine Chem. 2004, 125, 1939–1945. 
6. For the synthesis of fluorinated thiazole: (a) Campbell, T. F.; Stephens, C. E. J. Fluorine 
Chem. 2006, 127, 1591–1594. (b) Hatfield, J. M.; Eidell, C. K.; Stephens, C. E. Tetrahedron 
Lett. 2013, 54, 1025–1028. 
7. (a) Breen, J. R.; Sandford, G.; Yufit, D. S.; Howard, J. A. K.; Fray, J.; Patel, B. Beilstein J. 
Org. Chem. 2011, 7, 1048–1054. (b) Breen, J. R.; Sandford, G.; Patel, B.; Fray, J. Synlett 
2015, 26, 51–54. 
8. (a) Caterina, M. J.; Schumacher, M. A.; Tominaga, M.; Rosen, T. A.; Levine, J. D.; Julius, D. 
Nature 1997, 389, 816–824. (b) Szallasi, A.; Cortright, D. N.; Blum, C. A.; Eid, S. R. Nat. 
Rev. Drug Discovery 2007, 6, 357-372. 
9. (a) Palin, R.; Abernethy, L.; Ansari, N.; Cameron, K.; Clarkson, T.; Dempster, M.; Dunn, D.; 
Easson, A.-M.; Edwards, D.; Maclean, J.; Everett, K.; Feilden, H.; Ho, K.-K.; Kultgen, S.; 
Littlewood, P.; McArthur, D.; McGregor, D.; McLuskey, H.; Neagu, I.; Neale, S.; Nisbet, L.-
A.; Ohlmeyer, M.; Pham, Q.; Ratcliffe, P.; Rong, Y.; Roughton, A.; Sammons, M.; Swanson, 
R.; Tracey, H.; Walker, G. Bioorg. Med. Chem. Lett. 2011, 21, 892-898. (b) Roughton, A. L.; 
Ho, K.-K.; Ohlmeyer, M.; Neagu, I.; Kultgen, S. G.; Ansari, N.; Rong, Y.; Ratcliffe, P. D.; 
Palin, R. PCT Int. Appl. WO2009016241 A1, 2009. 
10. Sheldrick, G. M., Acta Cryst., Sect. A: 2008, 64, 112-122. 
11. Dolomanov, O. V., Bourhis, L. J., Gildea, R. J., Howard, J. A. K., Puschmann H., 
J.Appl.Cryst., 2009, 42, 339-341.
